Search Results for “EC” – Page 51 – media

New Analysis Method Detects Pathogens in Blood Faster and More

Globally, an alarming one in every five deaths is attributed to complications related to sepsis, with children accounting for 41% of these fatalities. The urgency in detecting sepsis is paramount since the risk of mortality increases by 4% for each hour the infection remains undiagnosed or treated incorrectly. Common practice involves administering antibiotics to sepsis patients while waiting for blood culture results, which can contribute to antibiotic resistance. Ineffectively treating sepsis can be detrimental, as up to 30% of patients receive incorrect treatments, further elevating their risk of death. The critical nature of timely and accurate diagnosis in sepsis cases is underscored by the fact that the mortality risk escalates by 4% every hour the infection is not properly identified or treated. Now, a new analysis technique offers quicker and more precise pathogen detection in blood samples compared to traditional blood cultures, which are the standard in infection diagnosis. The ...
- Source: drugdu
- 123
- February 24, 2024
Ultra-Sensitive Blood Test Reflects Brain Damage and Predicts Functional Outcomes after Ischemic Stroke

Acute ischemic stroke, which is the most common type of stroke, occurs due to a lack of oxygen in the brain caused by a blood clot. Currently, there are no blood-based biomarkers that can accurately reflect the acute neuronal damage following a stroke or predict the clinical outcomes for stroke patients. Now, a new study has demonstrated that an ultra-sensitive blood test can reflect brain damage and also predict functional outcomes after acute ischemic stroke. Brain-derived tau (BD-tau), a protein indicative of neuronal breakdown in the central nervous system, particularly in Alzheimer’s disease, has been the focus of recent research. Last year, a team from the University of Gothenburg (Gothenburg, Sweden) developed a novel blood test to measure BD-tau levels. This breakthrough represents a significant step towards creating a tool for tracking and monitoring Alzheimer’s disease progression. In their latest research, this team explored whether BD-tau could also serve as ...
- Source: drugdu
- 159
- February 23, 2024
Gold-Enhanced Nanopore Sensors Detect Ovarian Cancer Biomarkers in Urine Samples

The key to defeating cancer lies in its early and accurate diagnosis. Clinical data underscores this, revealing a significant 50-75% increase in the five-year survival rate when cancers are identified in their initial stages. This is true for various types of cancer, including ovarian cancer, which is notoriously challenging to diagnose. Mass spectrometry has been instrumental in discovering thousands of peptides in the urine of ovarian cancer patients, indicating their potential as biomarkers for the disease. However, the application of mass spectrometry in clinical settings is limited, prompting the need for alternative methods to detect these peptides. Now, a new study has found a novel technique to be effective in identifying specific biomarkers found in the urine of ovarian cancer patients, a development that could eventually aid doctors in diagnosing the disease more accurately. Researchers from Virginia Commonwealth University (VCU, Richmond, VA, USA) employed a combination of gold nanoparticles and ...
- Source: drugdu
- 196
- February 23, 2024
Bavarian Nordic Hones Infectious Disease Focus by Dropping Cancer Vaccine R&D

Bavarian Nordic will concentrate on its portfolio and pipeline of infectious diseases vaccines, including top seller Jynneos, approved for mpox and smallpox. The company only had one clinical-stage cancer vaccine program. By FRANK VINLUAN The mpox outbreak is a memory, but Bavarian Nordic, maker of the only FDA-approved vaccine for the pathogen behind this viral infection, turned skyrocketing demand for its product into record revenue. With that growth comes a need to focus, and the pure-play vaccines company is getting out of the business of developing vaccines for cancer. Bavarian Nordic’s lone cancer vaccine candidate, TAEK-VAC, had reached Phase 1 testing as a potential treatment for chordoma or HER2-positive breast cancer. But this program had also reached the point where further investment is needed, and Bavarian Nordic decided it needs to focus its R&D efforts on infectious disease, the Denmark-based company said Wednesday in its announcement of preliminary 2023 financial ...
- Source: drugdu
- 151
- February 23, 2024
Pfizer’s Velsipity granted EC approval for ulcerative colitis in patients aged from 16 years

Pfizer’s S1P receptor modulator Velsipity (etrasimod) has been approved by the European Commission (EC) to treat moderately-to-severely active ulcerative colitis (UC) in patients aged 16 years and older. Those eligible for the drug, which is now the first and only oral advanced UC therapy approved in the EU for this patient population, will have had an inadequate response, lost response or been intolerant to conventional therapy or a biological agent. Affecting approximately 2.6 million people in Europe, UC is a chronic, immune-mediated condition where the colon and rectum become inflamed, causing symptoms such as frequent diarrhoea, bowel urgency, rectal bleeding, abdominal pain, fatigue, fever and anaemia. The EC’s decision on Velsipity follows a recommendation from the European Medicines Agency’s human medicines committee in December and was supported by positive results from the late-stage ELEVATE UC registrational programme. The ELEVATE UC 52 and ELEVATE UC 12 studies, which evaluated Velsipity 2mg ...
- Source: drugdu
- 104
- February 23, 2024
Kangpu Biopharmaceuticals to Present Preclinical Efficacy Data of KPG-818 in Crohn’s Disease at the 19th Congress of ECCO (IND Application for Phase II in Progress)

HEFEI, China, Feb. 20, 2024 /PRNewswire/ — Kangpu Biopharmaceuticals, a clinical-stage company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, autoimmune diseases, and inflammation, through targeted protein degradation technology, today announced that a poster on preclinical efficacy data of KPG-818 in Crohn’s disease will be presented at the upcoming 19th Congress of European Crohn’s and Colitis Organisation (ECCO), taking place in Stockholm, Sweden, February 21-24, 2024. Poster Title: Therapeutic Effects of KPG-818 in a Trinitrobenzene Sulfonic Acid-Induced Mouse Crohn’s/Ulcerative Colitis Model Abstract Number: EC24-0844 Exhibition Zone: Poster Exhibition, Hall A Presentation Number: P131 Crohn’s disease is a chronic and difficult-to-treat autoimmune disorder. The current available therapeutic options for this condition are very limited, and there remain significant unmet medical needs. In preclinical studies, KPG-818 demonstrated potent therapeutic efficacy in mouse model of Crohn’s disease. KPG-818 significantly improved clinical symptoms, colorectitis, ulcers, and local immune ...
- Source: drugdu
- 112
- February 23, 2024
WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics

SHANGHAI, Feb. 21, 2024 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized as a 2024 Industry Top-Rated and Regional Top-Rated Company by Morningstar Sustainalytics’ Environmental, Social and Governance (ESG) Ratings, marking the fourth consecutive year the company has achieved this honor. Sustainalytics is a leading ESG data, research, and ratings firm that supports global investors with the development and implementation of responsible investment strategies. Its 2024 ESG Ratings cover more than 14,000 companies across 42 industries worldwide, with Top-Rated Badges given to those companies with the strongest ESG achievements. WuXi Biologics ranks in the top 2% of the nearly 1,000 companies assessed in the pharmaceutical sector. Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, “We are very pleased to once again receive this honor from Morningstar Sustainalytics, which is a strong ...
- Source: drugdu
- 126
- February 23, 2024
Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine

Currently, mammography is the standard method for breast cancer diagnosis, but it has several limitations. The primary concern with mammograms is their lack of infallibility. False negatives can occur when normal breast tissue conceals cancer, and false positives may arise from anomalies that resemble cancer but are benign, causing unnecessary anxiety for patients. Additionally, the radiation involved in these tests could potentially contribute to the development of cancer over time. Now, a pain-free, low-cost, sensitive, radiation-free device that can detect breast cancer in urine with a sensitivity of 88.33% could bring about a shift in the diagnostic approach toward this disease. The Blue Box Biomedical Solutions (Barcelona, Spain) has developed an affordable, user-friendly, and portable device that can detect breast cancer using a urine sample. This device, known as the Blue Box, employs an innovative eNose (electronic nose) to detect the smell of urine. It features a chemical sensor array ...
- Source: drugdu
- 139
- February 22, 2024
Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step

Hepatitis B, a significant global health concern, is responsible for chronic liver diseases like cirrhosis and liver cancer which is one of the most common cancers worldwide. The challenge with hepatitis B is that most carriers are asymptomatic, remaining unaware of their infection, which can lead to its unintentional spread. Thus, early diagnosis is vital to halt the spread, initiate timely treatment, and reduce the risk of liver complications primarily caused by the hepatitis B virus. However, conventional tests for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) are complex, requiring specialized skills and large, expensive machine-based assays typically found in major hospitals. To overcome the problem of inadequate access to screening for Hepatitis B, researchers have developed a wireless, point-of-care test for the Hepatitis B Virus that can make diagnosis simpler and faster. Researchers from Chulalongkorn University (Bangkok, Thailand) have developed a testing kit that enables ...
- Source: drugdu
- 92
- February 22, 2024
AstraZeneca’s Tagrisso combination approved by FDA for advanced lung cancer

AstraZeneca’s (AZ) Tagrisso (osimertinib) has been approved by the US Food and Drug Administration (FDA) in combination with chemotherapy to treat a subset of advanced lung cancer patients. The epidermal growth factor receptor-mutated (EGFR)-tyrosine kinase inhibitor has specifically been authorised for use alongside chemotherapy in adults with locally advanced or metastatic EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). An estimated 200,000 people in the US are diagnosed with lung cancer each year and NSCLC accounts for up to 85% of all lung cancer cases. Approximately 15% of NSCLC patients in the US have an EGFRm, with this population “particularly sensitive” to treatment with an EGFR-tyrosine kinase inhibitor that blocks the cell-signalling pathways that drive the growth of tumour cells, AZ said. The FDA’s decision was supported by positive results from the late-stage FLAURA2 trial, which randomised more than 500 patients with locally advanced or metastatic EGFRm NSCLC to receive the ...
- Source: drugdu
- 128
- February 22, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.